« Return to News | Drug Sponsors | R&D Trends

Neuroscience drug development slows, requires funding

Tuesday, March 29, 2011 11:49 AM

Many European pharmaceutical companies have significantly reduced their workflow in the realm of neuroscience, according to Fierce Biotech. Companies are challenged with a high risk of trial failure while investors demand new products. 

GlaxoSmithKline was the first to leave the specialty area, followed by AstraZeneca and Sanofi-aventis. Even Merck in the U.S. is cutting back. Now the neuroscience disease groups say it expects to see fewer new drugs being added to its portfolio—with potentially alarming consequences for patients.

The Tufts Center for the Study of Drug Development said clinical trial costs for neuroscience programs tend to be more expensive than other fields, even as the approval rate for new drugs is lower.

Dr. Mary Baker, president of the European Federation of Neurological Associations, told the Wall Street Journal, "One key reason is that there are few proven biomarkers in CNS [central nervous system] diseases, so it means expensive research for potentially little gain." 

Patrick Vallance, chief of medical R&D at GSK, said new programs will need to be backed by public collaborators that can help fund the research if work is to continue in this field. Others said more money needs to be spent on basic research that can help identify new drugs that can do more for patients.

"Neurosciences research in many areas is very exciting, but in some areas is not mature enough to make drug discovery efficient or effective today—which is why I believe that further investment is needed, and have argued the case for public-sector funding in this area," says Vallance.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.